A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus-Reference-Cited by-同舟云学术

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Published:2011-11-29 Issue:12 Volume:63 Page:3918-3930
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Furie Richard,Petri Michelle,Zamani Omid,Cervera Ricard,Wallace Daniel J.,Tegzová Dana,Sanchez-Guerrero Jorge,Schwarting Andreas,Merrill Joan T.,Chatham W. Winn,Stohl William,Ginzler Ellen M.,Hough Douglas R.,Zhong Z. John,Freimuth William,van Vollenhoven Ronald F.,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.30613/fullpdf

Reference34 articles.

1. Guidelines for referral and management of systemic lupus erythematosus in adults;American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines;Arthritis Rheum,1999

2. Mortality in systemic lupus erythematosus;Bernatsky;Arthritis Rheum,2006

3. Systemic lupus erythematosus;D'Cruz;Lancet,2007

4. The socioeconomic burden of SLE;Lau;Nat Rev Rheumatol,2009

5. B cells move to centre stage: novel opportunities for autoimmune disease treatment;Browning;Nat Rev Drug Discov,2006

Cited by 1320 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic glucocorticoid therapy for SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Future directions;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Management of lupus nephritis;Dubois' Lupus Erythematosus and Related Syndromes;2025

4. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

5. Clinical markers, metrics, indices, and clinical trials;Dubois' Lupus Erythematosus and Related Syndromes;2025